Arbutus Biopharma settles litigation with Acuitas Therapeutics.
Arbutus Biopharma Corporation announced that litigation initiated by Acuitas Therapeutics on October 25, 2016 in the Supreme Court of British Columbia has been settled before trial. The litigation centered on Acuitas' rights to use and sublicense Arbutus pre-April 15, 2010 LNP technology under a cross license agreement dated November 12, 2012. On February 7, 2017, Arbutus obtained an injunction preventing Acuitas from further providing Arbutus LNP technology to any third party. The settlement stipulates that the four non-exclusive viral vaccine sublicenses previously granted to Moderna are the only sublicenses to survive. These four sublicenses, previously granted by Acuitas to Moderna under the pre-April 15, 2010 Arbutus LNP patent families, are each limited to a specific viral target. Moderna has no other rights to Arbutus' broad suite of LNP intellectual property.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 22, 2018|
|Previous Article:||First Financial Bancorp and MainSource Financial granted merger approval.|
|Next Article:||Xcerra and Hubei Xinyan withdraw CFIUS application, terminate merger.|